- Latest available (Revised)
- Original (As made)
There are currently no known outstanding effects for the The Human Medicines (Amendment) (No. 3) Regulations 2015.
Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.
Statutory Instruments
Medicines
Made
9th July 2015
Laid before Parliament
16th July 2015
Coming into force
1st October 2015
The Secretary of State and the Minister for Health, Social Services and Public Safety make the following Regulations. They do so in the exercise of the powers conferred by section 2(2) and (5) of the European Communities Act 1972 M1, having been designated for the purposes of section 2(2) of that Act in relation to medicinal products M2.
Marginal Citations
M11972 c.68. Section 2(2) was amended by section 27(1)(a) of the Legislative and Regulatory Reform Act 2006 (c.51) and section 3(3) of and Part 1 of the Schedule to the European Union (Amendment) Act 2008 (c.7). Section 2(5) was amended by section 41(1) of and Part 1 of Schedule 6 to the Northern Ireland Constitution Act 1973 (c.36).
M2See S.I. 1972/1811 regarding the designation of Ministers.
1. These Regulations may be cited as the Human Medicines (Amendment) (No. 3) Regulations 2015 and shall come into force on 1st October 2015.
2. The Human Medicines Regulations 2012 M3 are amended as follows.
Marginal Citations
M3S.I. 2012/1916 as amended by S.I. 2013/235,
1855 and
2593,
2014/490 and
1878 and
2015/323 and
903.
3.—(1) Regulation 8 M4 (general interpretation) is amended as follows.
(2) In paragraph (2), for “18(7) and (8)” substitute “ 18(4) and (5) ”;
(3) In paragraph (3), for “18(8)” substitute “ 18(5) ”; and
(4) In paragraph (4), for “18(8)” substitute “ 18(5) ”.
Marginal Citations
M4Regulation 8 was amended by S.I. 2013/1855 and
2593.
4. In regulation 38 (imports from states other than EEA states), in paragraph (3)(b), for the words from “the principles” to the end substitute “ good manufacturing practice for active substances ”.
5. In regulation 39 M5 (further requirements for manufacturer's licence), in paragraph (8), for “44(4) to (6)” substitute “ 44(5) and (6) ”.
Marginal Citations
M5Regulation 39 was amended by S.I. 2013/1855.
6.—(1) Regulation 44 M6 (requirements for wholesale dealers to deal only with specified persons) is amended as follows.
(2) Omit paragraph (1).
(3) In paragraph (2)—
(a)for “From 28th October 2013 the” substitute “ The ”;
(b)after sub-paragraph (b), insert “ or ”;
(c)in sub-paragraph (c), for “country A; or” (at the end of the sub-paragraph) substitute “ country A. ”;
(d)omit sub-paragraph (d).
(4) In paragraph (3), omit “(1),”.
(5) Omit paragraph (4).
(6) In paragraph (5), for “From 28th October 2013, the” substitute “ The ”.
Marginal Citations
M6Regulation 44 was substituted by S.I. 2013/1855.
7.—(1) Regulation 233 M7 (exemption for supply etc under a PGD by person conducting a retail pharmacy business) is amended as follows.
(2) In paragraph (1)(a), after paragraph (ivc) insert—
“(ivd)Public Health England,
(ive)Public Health Agency,”.
(3) In paragraph (5), in sub-paragraph (a) for “to (ivc) (health bodies), on behalf of that body” substitute “ to (ive) (health bodies), by or on behalf of the person specified in column 2 of Part 2 of Schedule 16 against the entry in column 1 for that body ”.
Marginal Citations
M7Regulation 233 was amended by S.I. 2013/235
8. In regulation 256E M8 (removal of a person's entry from the list), in paragraph (a), for “256I(1)(b)” substitute “ 256I(1)(c) ”.
Marginal Citations
M8Regulation 256E was inserted by S.I. 2013/1855.
9.—(1) Regulation 346 M9 (Secretary of State to carry out a review of certain provisions) is amended as follows.
(2) In paragraph (2)—
(a)in sub-paragraph (c) after paragraph (xxviiif) M10 insert—
“(xxviiifa)233(1)(a)(ivd) and (ive),”; and
(b)in sub-paragraph (d), for paragraph (iva) M11 substitute—
“(iva)17, Part 1 item 12, Part 2 items 4a and 11, Part 4 items 11 and 12 and Part 5 items 7a and 18,”.
Marginal Citations
M9Regulation 346 was substituted by S.I. 2013/1855.
M10Paragraph (xxviiif) was inserted by S.I. 2015/323.
M11Paragraph (iva) was substituted by S.I. 2014/1878.
10.—(1) Schedule 17 (exemption for sale, supply or administration by certain persons) is amended as follows.
(2) In Part 2 M12 (exemption from the restriction on supply of prescription only medicines), after item 4 in the table add—
4a Persons employed or engaged in the provision of drug treatment services provided by, on behalf of or under arrangements made by one of the following bodies– (a) an NHS body; (b) a local authority; (c) Public Health England; or (d) Public Health Agency. | 4a A prescription only medicine for parenteral administration containing naloxone hydrochloride but no other substance that is classified as a product available on prescription only. | 4a The supply shall be only in the course of provisions of lawful drug treatment services and only where required for the purpose of saving life in an emergency. |
(3) In Part 5 M13 (exemptions from the restrictions in regulation 220 and 221 for certain persons who supply certain medicinal products), after item 7 in the table add—
7a Persons employed or engaged in the provision of drug treatment services provided by, on behalf of or under arrangements made by one of the following bodies– (a) an NHS body; (d) a local authority; (c) Public Health England; or (d) Public Health Agency. | 7a A prescription only medicine for parenteral administration containing naloxone hydrochloride but no other substance that is classified as a product available on prescription only. | 7a The supply shall be only in the course of provisions of lawful drug treatment services and only where required for the purpose of saving life in an emergency. |
Signed by the authority of the Secretary of State.
Jane Ellison
Parliamentary Under-Secretary of State,
Department of Health
9th July 2015
Simon Hamilton
Minister for Health, Social Services and Public Safety
9th July 2015
(This note is not part of the Regulations)
These Regulations amend the Human Medicines Regulations 2012 (the 2012 Regulations).
Regulation 7 amends regulation 233 of the 2012 Regulations to enable Public Health England and the Regional Agency for Public Health and Social Well-being in Northern Ireland to enter into arrangements with retail pharmacists to supply prescription only medicines under a patient group direction (PGD). A PGD is a written instruction for the supply or administration of medicines to patients in defined clinical situations without the need for a prescription.
Regulation 10 amends Schedule 17 to the 2012 Regulations to enable the prescription only medicine naloxone hydrochloride to be supplied by drug treatment services for the purpose of saving life in an emergency.
Regulation 9 amends the 2012 Regulations so that the new provisions relating to patient group directions and to drug treatment services are subject to review by the Secretary of State.
Additionally, regulations 3 to 6 and 8 make minor corrections, including updating cross-references and removing obsolete provisions in the 2012 Regulations.
A full impact assessment of the effect that this instrument will have on the costs of business and the voluntary sector is available from the Medicines and Healthcare products Regulatory Agency, 151 Buckingham Palace Road, Victoria, London SW1W 9SZ and is published with the Explanatory Memorandum alongside the instrument on www.legislation.gov.uk.
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Impact Assessments generally accompany all UK Government interventions of a regulatory nature that affect the private sector, civil society organisations and public services. They apply regardless of whether the regulation originates from a domestic or international source and can accompany primary (Acts etc) and secondary legislation (SIs). An Impact Assessment allows those with an interest in the policy area to understand:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: